Skip to content
Screener

Tandem Diabetes Care TNDM Q2 2026 earnings

Reported August 6, 2026 · After market close

Revenue$254.6MMiss by $429.9K
EPS-$0.31Beat by $0.01
Revenue estimate$255.0M
EPS estimate-$0.32
“Our second quarter results reflect meaningful progress across the priorities we set for 2026. We are seeing tangible evidence that our strategy is gaining traction and the momentum we are building reinforces our confidence in Tandem's ability to drive broader customer impact, strengthen our financial performance and create long-term value.”
John Sheridan

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$266.1M
EPS estimate-$0.26

Financials

Q2 2026

Income statement

See full
Revenue$254.6M+5.8%
Gross profit$144.8M+15.0%
Operating income-$13.8M+73.4%
Net income-$21.2M+59.6%
EPS (diluted)-$0.31+60.3%

Balance sheet

See full
Cash & equivalents$62.8M-2.0%
Total debt$739.3M+64.6%
Total equity$130.4M-2.2%
Total assets$1.2B+31.8%

Cash flow

See full
Operating cash flow-$34.6M-265%
CapEx$4.1M-34.7%
Free cash flow-$38.7M-146%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$1.22B+48.2%
Enterprise value$1.9B+57.0%
P/S1.2×+0.3×

Profitability

See full
Gross margin56%+3.5pp
Operating margin-4.4%-1.9pp
Net margin-6.1%-2.5pp

Returns & leverage

See full
Return on equity-48%-17.5pp
Debt / equity5.7×+2.3×
Current ratio3.2×+0.7×

Segments

By product

See full
Supplies and other$139.9M+8.6%
Pump$114.7M+2.5%

FAQ

When did Tandem Diabetes Care report Q2 2026 earnings?
Tandem Diabetes Care (TNDM) reported Q2 2026 earnings on August 6, 2026 after market close.
What were Tandem Diabetes Care's Q2 2026 revenue and EPS?
Tandem Diabetes Care reported revenue of $254.6M and eps of $-0.31 for Q2 2026.
Did Tandem Diabetes Care beat estimates in Q2 2026?
Revenue missed the consensus estimate of $255.0M by $429.9K. EPS beat the consensus estimate of $-0.32 by $0.01.
How did Tandem Diabetes Care's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 5.8% from $240.7M a year earlier and eps grew 35.4% from $-0.48.
Where can I find Tandem Diabetes Care's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001438133-26-000124) and the 10-Q periodic report (0001438133-26-000125) directly on SEC EDGAR. The filing index links above go to sec.gov.